

ICD-10 Procedure Coding System (ICD-10-PCS) 2020 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

XW0

No change	<i>Section</i>	X New Technology		
	<i>Body System</i>	W Anatomical Regions		
	<i>Operation</i>	0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2020	1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance W Caplacizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective 3 Idarucizumab, Dabigatran Reversal Agent 4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
FY2020	3 Peripheral Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody B Cytarabine and Daunorubicin Liposome Antineoplastic C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
FY2020	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
FY2020	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
FY2020	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
FY2020	3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
FY2020	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
FY2020	3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
FY2020	3 Peripheral Vein	3 Percutaneous	H Tocilizumab K Fosfomycin Anti-infective N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective 3 Idarucizumab, Dabigatran Reversal Agent 4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1

No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
FY2020	4 Central Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody B Cytarabine and Daunorubicin Liposome Antineoplastic C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
FY2020	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
FY2020	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
FY2020	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
FY2020	4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
FY2020	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
FY2020	4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
FY2020	4 Central Vein	3 Percutaneous	H Tocilizumab K Fosfomycin Anti-infective N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
FY2020	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic L Erdafitinib Antineoplastic R Venetoclax Antineoplastic T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5

XW1

FY2020	<i>Section</i> X New Technology <i>Body System</i> W Anatomical Regions <i>Operation</i> 1 Transfusion: Putting in blood or blood products			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2020	3 Peripheral Vein 4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5